Q (sonnet): For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?

═ answer (success)
I can help you explore EML4-ALK fusion variant data in cBioPortal, but I need to flag an important limitation before doing so: **this question, as posed, isn't something cBioPortal data can answer.**

Here's why:

1. **Quality of life data**: cBioPortal does not collect or store patient-reported quality of life measures (e.g., symptom burden, functional status, psychosocial outcomes). This type of data isn't part of the genomic/clinical datasets in the portal.

2. **Secondary cancer risk**: cBioPortal contains cross-sectional genomic and clinical annotations for tumor samples (mutations, copy number, fusions, and some clinical fields like survival months/status, stage, treatment). It is not a longitudinal cancer-registry or epidemiological resource designed to calculate incidence rates of subsequent primary malignancies. A few studies include some follow-up/outcome fields, but there is no systematic "secondary cancer" endpoint tracked across studies, and no study is designed or powered to answer this causally.

3. **Fusion variant breakdown (EML4-ALK)**: What I *can* do reliably is query which lung cancer studies in cBioPortal have ALK fusion (including EML4-ALK) calls, and — if breakpoint/variant-level detail happens to be annotated — show how many patients have each variant and link you to their clinical records (survival status/months, stage, treatment history if present). That would be a factual, descriptive result, not an analysis of long-term quality of life or secondary malignancy risk.

**What I'd suggest instead**, depending on what you're actually after:
- If you want to see EML4-ALK fusion prevalence and variant breakdown in a specific lung cancer cohort (e.g., TCGA LUAD, MSK-IMPACT lung studies), I can pull that and link you to the relevant OncoPrint/Results View.
- If you want survival outcomes (OS/PFS) associated with different EML4-ALK fusion variants in a study that has that granularity, I can retrieve per-variant patient counts and event/censoring counts and link you to the Group Comparison Survival tab (which runs the proper Kaplan-Meier statistics — I won't fabricate a median survival number myself).
- For quality-of-life outcomes and secondary malignancy risk, you would need a different data source — e.g., a clinical registry, a dedicated ALK-fusion natural history study, or published literature — which is outside what this tool can retrieve.

Would you like me to proceed with the fusion-variant/survival query in a specific lung cancer study (e.g., TCGA PanCancer Atlas LUAD, or an MSK lung cohort), acknowledging the scope limits above?